A feature article called "Beijing Continuum: World's First Original Treatment for Liver Fibrosis Due to Hepatitis B will soon be released!" was published in Beijing's municipal financial media "Beijing Time".

It describes the schedule for F351 and the expansion of the manufacturing system for Iceurui.
Regarding F351, the acquisition of Phase 3 clinical trial data is scheduled for the fourth quarter of 2024, and the sales application (listing) is planned to be completed in 2025. Also, Iceurui can be manufactured up to 1.2 billion yuan (about 24 billion yen) by expanding the production line.

Photos of the manufacturing process and other details are also included, so please take a look at them below.
Kangtini Pharmaceuticals: The world's first original chemical drug to treat hepatitis B-induced liver fibrosis is about to be released!_Beijing Time (btime.com)

*The title of this article is a reference translation. Please note that the content of the original article takes precedence if there is any discrepancy with the content.